Clinical trial
A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C
NCT04070235 is registered in ClinicalTrials.gov with Nanjing Sanhome Pharmaceutical, Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C
- Lead sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Phase
- Phase 2/3
- Overall status
- Unknown status
- Start date
- March 29, 2019
- Completion date
- August 31, 2020
- Enrollment
- 440 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.